tqb2618
Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 1Active
C
37/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 65/ 100
Competitive context
449 Active assets in the Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf Ultimovacs ASA | Phase 4 | BBB |
Sargramostim Mayo Clinic | Phase 3 | BBB |
Cediranib M.D. Anderson Cancer Center | Phase 3 | BBB |
Ifa Craig L Slingluff, Jr | Phase 2 | BB |
Tebentafusp Immunocore Ltd | Phase 3 | BB |
View all 50 →
Same molecule, other indications
tqb2618 is also rated in:
Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic SyndromesDormant
CC
Indicative ·
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →